Catalyst Wire Dossier Catalyst Wire Dossier

Tanruprubart

ANX005 · Annexon, Inc.
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Tanruprubart, covering 2026-02-20 to 2026-02-20. Get the full timeline:

Most recent: Clinical Trial Update: An Open Label Clinical Study to Evaluate Tanruprubart (Also Commonly Known as ANX005) in Participants With Guillain-Barré Syndrome (FORWARD Study) [Phase 3]

See pricing